Myriad Genetics Reports myRisk Cancer Test Improves Colon Cancer Testing by 60%
October 07, 2013 at 07:09 AM EDT
Myriad Genetics, Inc. (Nasdaq: MYGN ) today announced new clinical data from a study with myRisk Hereditary Cancer, a 25-gene hereditary cancer panel, that showed a 60 percent increase in mutations detected in cancer predisposition genes in patients with a prior history of colon cancer and/or polyps. Myriad is presenting this clinical study and